Bayon Therapeutics is an ophthalmic specialty pharmaceutical company using small molecules to restore the eyes’ ability to perceive and interpret vision in visually-impaired patients. Bayon was founded in 2020 with the focus on developing a novel platform of small molecules for visually-impaired patients with high unmet needs. The company's initial clinical trials focus on patients in later stages of disease progression due to retinitis pigmentosa, includinfg all sub-forms. After demonstrating safety and efficacy, Bayon plans to further develop the platform for use in patients with geographic atrophy, the later stages of age-related macular degeneration (dry AMD).
Formerly known as Yellowbrick Bio.